FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Regulation FD Disclosure

FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01 Regulation FD Disclosure.

On January 5, 2017, Fibrocell Science, Inc. (the “Company”)
issued a press release announcing that the U. S. Food and Drug
Administration has granted Fast Track designation to FCX-007, the
Companys clinical-stage candidate for the treatment of Recessive
Dystrophic Epidermolysis Bullosa. A copy of the press release is
furnished herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release dated January 5, 2017


About FIBROCELL SCIENCE, INC. (NASDAQ:FCSC)

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Recent Trading Information

FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) closed its last trading session up +0.178 at 0.858 with 59,925 shares trading hands.

An ad to help with our costs